Hodgkin lymphoma

Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

Hodg·kin lymphoma

 (hŏj′kĭn) or Hodg·kin's lymphoma (-kĭnz)
A lymphoma typically characterized by the presence of Reed-Sternberg cells and producing symptoms that include enlarged lymph nodes and spleen, fever, night sweats, weight loss, and itching. Also called Hodgkin's disease.

[After Thomas Hodgkin (1798-1866), British physician.]
References in periodicals archive ?
Objective: The objective of this study was to determine the frequency of bone marrow infiltration along with various histological patterns of bone marrow infiltration in previously diagnosed patients of Non Hodgkin Lymphoma.
Our aim was to detect Epstein Barr virus LMP-1 antigen in subtypes of Classical Hodgkin Lymphoma in Peshawar district of Khyber Pakhtunkhwa Province of Pakistan.
Takeda Pharmaceutical Company Limited will present data on ADCETRIS (brentuximab vedotin) in Hodgkin lymphoma at the 10th International Symposium on Hodgkin Lymphoma (ISHL), October 22 25, 2016 in Cologne, Germany.
Hodgkin Lymphoma is most commonly seen in the lung as secondary involvement.
Non-Hodgkin lymphomas can occasionally present with morphologic features that resemble classical Hodgkin lymphoma.
Hodgkin Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
This case report is established based on observation of Hodgkin lymphoma in parotid lymph node before and after slaughter.
M2 PHARMA-December 7, 2010-Novartis' LBH589 shows disease control, tumor reduction in pretreated Hodgkin lymphoma patients(C)2010 M2 COMMUNICATIONS
The category of Hodgkin lymphoma includes classical Hodgkin lymphoma (CHL) and the less common nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).
and Takeda Pharmaceutical Company Limited today announced the final data of the ADCETRIS (brentuximab vedotin) monotherapy pivotal Phase 2 clinical trial in relapsed or refractory classical Hodgkin lymphoma were published in the journal Blood.